肝动脉灌注化疗联合免疫靶向治疗 在晚期肝细胞癌中的临床疗效


Clinical efficacy of hepatic artery infusion chemotherapy combined with immunotherapy plus target therapy for advanced hepatocellular carcinoma

  • 摘要: 原发性肝癌是常见的恶性肿瘤之一,病死率居全世界第 3位。由于早期肝癌无明显症 状,大部分病人确诊时已属于中晚期,失去手术切除机会。笔者报道1例肝细胞癌伴门静脉癌栓病人 行肝动脉灌注化疗联合阿替利珠单克隆抗体+贝伐珠单克隆抗体治疗的临床经验,其研究结果显示: 病人肿瘤及癌栓明显消退,治疗方案安全、有效。

     

    Abstract: Primary liver cancer is one of the common malignant tumors and its mortality ranks third in the world. Because there are no obvious symptoms in the early stage of liver cancer, most patients are diagnosed as advanced stage, without the opportunity of surgical resection. The authors report a case of hepatocellular carcinoma with portal vein tumor thrombus, which reduced significantly after hepatic artery infusion chemotherapy combined with bevacizumab and atezolizumab, showing the safety and efficacy

     

/

返回文章
返回